ClinicalTrials.gg
RecruitingNCT06724016Updated Nov 3, 2026

Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors

A Phase 1 interventional study of HM16390 and pembrolizumab in Advanced or Metastatic Solid Tumors, sponsored by Hanmi Pharmaceutical Company Limited. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 3, 2026Site recruiting status changedStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
292
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of HM16390, as a single agent and in combination with pembrolizumab to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced or metastatic solid tumors.

Dose-Escalation Part is planned to establish the MTD or RDs for the randomized Dose-Ranging Part. Based on the results of the Dose-Escalation Part, additional eligible subjects will be randomized 1:1 into each dose level. After a comprehensive review of available data from both Dose-Escalation Part and Dose-Ranging Part, the RDEs to be tested in the Dose-Expansion Part are determined. Dose-Expansion Part is designed to assess the potential efficacy of HM16390 as a single agent and in combination with pembrolizumab when administered at the RDEs to subjects in indication-specific expansion cohorts.

02

Conditions studied

  • Advanced or Metastatic Solid Tumors
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a and/or cytologically confirmed advanced or solid tumor and have failed or are intolerant to standard therapy with clinical benefit.
  • Patients in the Dose-Escalation Part must have evaluable or at baseline and the patients for Dose-Ranging and Dose-Expansion Part must have at least one measurable lesion at baseline by computed tomography (CT) or magnetic resonance imaging (MRI) per (RECIST) v1.1.
  • (ECOG) performance status of 0 or 1 assessed within 7 days before allocation or randomization.
  • Age of 18 years or older (or country's legal age of majority if the legal age was >18 years)
  • Adequate renal function.
  • Adequate hematologic function.
  • Adequate liver function.

Key Exclusion Criteria:

  • Received prior treatment with agent targeting the IL-2, IL-7, or IL-15 receptors, or related to mode of action of HM16390.
  • Known active and/or carcinomatous meningitis.
  • History of severe toxicities associated with a prior immunotherapy.
  • Any prior treatment-related (i.e. chemotherapy, immunotherapy, radiotherapy) toxicities that have not resolved to Grade ≤ 1 per version 5.0 or prior treatment-related toxicities that are clinically unstable and clinically significant at time of enrollment.
  • Has ongoing or suspected disease.
  • Known active and clinically significant bacterial, fungal or viral infection including known (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness, patients.
  • History of chronic liver disease or evidence of hepatic cirrhosis.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
292 participants (estimated)

Study arms

  • Experimental
    HM16390

    HM16390 Monotherapy

    Drug: HM16390

  • Experimental
    HM16390 + pembrolizumab

    HM16390 in combination with pembrolizumab

    Drug: HM16390 · Drug: pembrolizumab

Interventions

  • DrugHM16390

    HM16390 will be administered subcutaneously using syringes on Day 1 of every 3-week treatment cycle

  • Fixed dose of pembrolizumab will be administered as an IV infusion over 30 minutes on Day 1 of every 3-week treatment cycle

    Also known as: KEYTRUDA®

06

What researchers measure

Primary outcomes

  1. Incidence and nature of DLTs

    To evaluate safety and tolerability of HM16390 as a single agent and in combination with pembrolizumab

    Time frame: At the end of Cycle 1 (each cycle is 21 days) in Dose-Escalation Part

  2. Incidence, nature, and severity of adverse events and laboratory abnormalities graded per NCI-CTCAE v5.0.

    To evaluate safety and tolerability of HM16390 as a single agent, and in combination with pembrolizumab

    Time frame: Throughout the study until end of safety follow-up period (90 days after the last treatment)

Secondary outcomes

  1. The maximum serum concentration (Cmax)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  2. The time to reach Cmax (Tmax)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  3. The area under the concentration-time curve from time 0 to the last observable concentration (AUClast)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  4. The AUC extrapolated to infinity (AUCinf)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  5. The AUC during the dosing interval (AUCtau)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  6. The serum concentration at the end of the dosing interval (Ctrough)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  7. The elimination half-life (T1/2)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  8. The apparent volume of distribution (Vd/F)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  9. The apparent clearance (CL/F)

    To evaluate PK profile upon HM16390 administration

    Time frame: Throughout the study until treatment discontinuation (up to 2-3 years)

  10. Objective response rate (ORR)

    ORR will be measured as the proportion of subjects with a confirmed response of complete response (CR) or partial response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

  11. Disease Control Rate (DCR)

    DCR will be measured as the proportion of subject with confirmed CR, PR, or Stable Disease (SD) as per RECIST v1.1

    Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

  12. Progression-free survival (PFS)

    PFS will be measured from date of first treatment until date of radiographic progression as per RECIST v1.1 or until death from any cause, whichever occurs first

    Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

  13. Duration of response (DOR)

    DOR will be measured as the time from initial onset of CR or PR to first radiographic progression as per RECIST v1.1 or death from any cause, whichever occurs first.

    Time frame: Throughout the study until disease progression or death whichever occurs first (up to 2-3 years)

07

Study locations

7 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Jul 2031, 79 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2024
First posted
Dec 9, 2024
StartActual
Dec 11, 2024
Primary completionEst.
Jul 2031
CompletionEst.
Jul 2031
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. Karmanos Cancer Institute is now Recruiting
Show site
  • The Regents of the University of California on behalf of its Los Angeles campus · Los Angeles, United States
Nov 3, 2026
Contact
Study contact changed: 6•••@hanmi.co.kr · •••9277→h•••@hanmi.co.kr · •••9835. See the current contact
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    1 site added. Karmanos Cancer Institute is now Recruiting
    Show site
    • The Regents of the University of California on behalf of its Los Angeles campus · Los Angeles, United States
    Contact Study contact changed: 6•••@hanmi.co.kr · •••9277→h•••@hanmi.co.kr · •••9835. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06724016
Responsible party
Sponsor
First posted
Dec 9, 2024
Start date
Dec 11, 2024
Primary completion
Jul 2031 (estimated)
Completion
Jul 2031 (estimated)
Last update
Nov 3, 2026

Study contacts

Hyebin Son
Contact
hyebin.son@hanmi.co.kr
82-2-410-9835

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion